Axsome Therapeutics (AXSM) Work In Process (2022 - 2026)

Axsome Therapeutics has disclosed Work In Process across 5 years of filings, most recently posting $15.5 million for Q1 2026.

• Work In Process for Q1 2026 came in at $15.5 million, up 127.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.5 million (up 127.41% YoY), and the FY2025 annual result was $17.8 million, up 130.95% from the prior year.
• Work In Process came in at $15.5 million for Q1 2026 at Axsome Therapeutics, down from $17.8 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $17.8 million in Q4 2025 to a low of $6.8 million in Q1 2025.
• The 5-year median for Work In Process is $10.5 million (2024), against an average of $11.0 million.
• Peak annual rise in Work In Process reached 130.95% in 2025, while the deepest fall reached 37.64% in 2025.
• Axsome Therapeutics' Work In Process stood at $14.0 million in 2022, then retreated by 26.34% to $10.3 million in 2023, then dropped by 24.92% to $7.7 million in 2024, then jumped by 130.95% to $17.8 million in 2025, then dropped by 13.34% to $15.5 million in 2026.
• The last three Work In Process figures came in at $15.5 million (Q1 2026), $17.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.